Startups
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
Rivus’ CMAs are designed to overcome these illnesses by activating the body’s natural process of mitochondrial uncoupling.
The company’s technology aims to precisely search out genetic mutations at their precise genome location, limiting concerns about toxicities or unwanted cellular changes.
The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases.
Two life sciences companies from two very different areas of medicine announced launches today. Here’s a look.
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
The new portfolio firm, Ancora Bio, is focused on developing a new drug to address treatment-resistant depression.
The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.
With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?
PRESS RELEASES